FredEHusserlMD

PubMed

• 11 citations
  A multicenter trial to evaluate the use of the CAPD "O" set.
  Lempert Kd, Kolb Ja, Swartz Rd, Campese, Thomas A. Golper
  ASAIO Transactions. 1986-07-01
• 297 citations
  Cinacalcet HCl, an Oral Calcimimetic Agent for the Treatment of Secondary Hyperparathyroidism in Hemodialysis and Peritoneal Dialysis: A Randomized, Double-Blind, Mult...
  Jill S. Lindberg, Bruce F. Culleton, Gordon Wong, Michael F. Borah, Roderick V. Clark
  Journal of the American Society of Nephrology. 2005-03-01
• 36 citations
  Elevated plasma levels of endostatin are associated with chronic kidney disease
  Jing Chen, L. Lee Hamm, Myra A. Kleinpeter, Fred Husserl, Islam Enver Khan
  American Journal of Nephrology. 2012-03-27

Journal Articles

• A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease  
  Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckhardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Re..., N Engl J Med, 1/19/2009
• Simulatneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCI  
  Sprague SM, Evenepoel P, Curzi MP, Gonzalez MT, Husserl FE, Kopyt N, Sterling LR, Mix C, Wong G, Clin J Am Soc Nephrol, 1/1/2009
• A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patents with comparable lipid control: th...  
  Qunibi W, Moustafa M, Muenz LR, He Dy, Kessler PD, Diaz-Buxo JA, Budoff M; CARE-2 Investigators, Am J Kidney Dis, 1/1/2008
• Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism  
  Block GA, Zeig S, Sugihara J, Chertow GM, Chi Em, Turner SA, Bushinsky DA; Target Investigators, Nephrol Dial Transplant, 1/1/2008
• Cinacalcet HCl, an oral calcimimmetic agent for the treatment of secondary hyperparatharoidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, mul...  
  Lindberg JS, Cullerton B, Wong G, Borah MF, Clark RV, Shapiro WB, Rodger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW, J Am Soc Nephrol, 1/1/2005
• Intraperitoneal Metoclopramide � Causing a Movement Disorder  
  Perez MG, Husserl, FE, Ross JL, Nephrology Dialysis and Transplantation, 1/1/2002
• Calcium Oxalate Agglomeration Inhibitions Reflect Renal Stone-Forming Activity  
  Lindberg J, Cole FE, Romani W, Husserl F, Fuselier H, Kok DJ, Erein DT, The Ochsner Journal, 1/1/2000
• Urine PH, Citrate, Urate (U), Tamm- Horsfall Protein (THP), and Calcium Oxalate (CO) Monohydrate Agglomeration inhibition [tm] in calcium oxalate stone formers (COSF) ...  
  Cole FE, Roman W, Kok DJ, Lindberg J, Husserl F, Erwin DT, Proceedings from the 8th European Symposium on Urolithiasis, 1/9/1999
• Band 3 Protein (B3P) in Calcium Oxalate Stone Formers (COSF)  
  Erwin D, Neitzschman H, Ward D, Allen J, Lindberg J, Husserl F, Fuselier H, Kok D, Cole F, Proceedings from the 8th European Symposium on Urolithiasis, 1/9/1999
• The Healthy Start Renal Clinic: Benefits of Tracking and Early Intervention in Pre-End Stage Renal Disease Patients  
  Self I, Lindberg J, Filangeri J, Anderson S, Szerlip M, Best J, Sadler R, Savoie J, Jackson D, James C, Husserl F, Copley JB, The Ochsner Journal, 1/1/1999
• Healthy Start Clinic: The Benefits of Tracking and Early Intervention in Pre-ESRD Patients  
  Self I, Lindberg J, Filangeri J, Husserl F, Slowik M, Sadler R, Anderson S, Szerlip M, Best M, Becker A, Contemporary Dialysis and Transplantation, 1/1/1999
• A Novel Use of Spent Peritoneal Dialysis Bags: An Inexpensive Waterbed  
  Husserl, FE, Peritoneal Dialysis International, 1/1/1998
• Agglomeration Inhibition Reflected Stone-Forming Activity During Long- Term Potassium Citrate Therapy in Calcium Stone Formers  
  Fuselier A, Moore K, Lindberg J, Husserl F, Cole F, Kok D, Whitehead D, Galliano D, Erwin D, Urology, 1/1/1998
• Plouimonas Oryzihabitans Peritonitis in CAPD  
  Cusimano A, Husserl FE, Peritoneal Dialysis International, 1/1/1997
• Treatment of calcium oxalate stone formers with potassium citrate  
  Lindberg J, Cole FE, Neusetzer S, Husserl F, Fuselier H, Kok D, Erwin DT, Proceedings from the Eighth International Symposium of Nephrolithiasis, 1/2/1996
• In-vitro calcium oxalate monohydrate (com) agglomeration [tm] and percent crystal growth (%GI) inhibited by phosphocitrate (PC) addition to stone former urines  
  Cole FE, Sallis JD, Lindberg J, Husserl F, Fuselier H, Kok DJ, Erwin DT, Proceedings from the Vlll International Symposium on Urolithiasis, 1/1/1996
• Urinary Tamm-Horsfall Protein Increased After Potassium Citrate Therapy of Calcium Oxalate Stone Formers  
  Fuselier HA, Allen JM, Marcucci PA, Ward DW, Lindberg JS, Husserl FE, Kok DJ, Turnipseed JT, Alam J, Cole FE, Erwin DT, Urology, Advances in Urology, 1/1/1995
• Effective Communication with Difficult People  
  Husserl FE, Proceedings National Kidney Foundation Spring Meeting, 1/1/1995
• Love  
  Husserl FE, 1/1/1995
• Improving the Physician-Patient Relationship Through Communication  
  Husserl FE, Southern Medicine, 1/1/1994
• Comunicacion Efectiva  
  Husserl FE, Rubiano MC, Hosmil Medica, 1/1/1994
• Eritropoyetina  
  Husserl FE, Hosmil Medica, 1/1/1994
• Calcium Oxalate Stone Agglomeration Reflects Stone Forming Activity: Inhibition Depends on Macromolecules Larger than 30 Kilodaltons  
  Erwin DT, Kok DJ, Alam J, Vaughn J, Coker K, Carriere B, Lindberg J, Husserl FE, Fuselier H, Cole F, AJKD, 1/1/1994
• Predicting Recurrent Renal Stones  
  Erwin DT, Kok DJ, Alam J, Vaughn J, Coker K, Carriere B, Lindberg J, Husserl FE, Fuselier H, Cole FE, American Journal of Kidney Diseases, 1/1/1994
• Communicating With Your Doctor: For Patients Only  
  Husserl FE, Husserl CR, 1/1/1994
• Join now to see all

Books/Book Chapters

• Current Clinical Practice 
  Chapter: Toxic nephropathies and drug usage in patients with renal impairment 
  Page 522 - 526Husserl FEEditors: Messerli FH.WB Saunders1987
• Current Clinical Practice 
  Chapter: Leg Cramps and Restless Leg. Current Clinical Practice 
  Page 67 - 68Messerli FH, Husserl FE, Ventura HOEditors: Messerli FH.WB Saunders1987

Abstracts/Posters

• Arterial Stiffness is Associated withVascular calcification In Chronic Kidney Disease
  Chen J, Townsend RR, Budoff MJ, Ahmed FA, Chen CS, Liu Y, Mills KT, Khan E, Laguardia HA, Kumbala DR, Kleinpeter MA, Husserl F, Simon EE, Hamm LL, He J, ASN, 1/1/2012
• Abnormail Nitric Oxide Metabolism, Prothrombotic state, Impaired Angiogenesis and risk of CKD
  Chen J, Hamm LL, Kleinpeter M, Husserl F, Khan E, Teran FJ, Browne G, Chen CS, Liu Y, Mills KT, Lustigova E, Xu R, Rogers S, Tarsia J, Shah K, He C, Alper AB, He J, ASN, 1/1/2011
• Association of Impaired Endotherlium-Dependant and Nitroglycerin-Induced Vasodilatation with Risk of Chronic Kidney Disease (CKD)
  Chen J, Hamm LL, Husserl F, Mohler ER, Arora R, Khan E, Alper B, Kleinpeter M, Sheneva R, Simon E, He J, ASN, 1/1/2010
• The Bony Truth: Vascular calcification in Chronic Kidney Disease
  Oleck S, Husserl F, ACP Annual Meeting, Toronto, Canada, 1/1/2010
• Lazarus, the Kidney Transplanee
  Haque NM, Keller R, Stryjwska B, Husserl F, The Ochsner Journal, 1/1/2008
• Impact of Evacuation Experience on Hemodialysis Access Infection Following Hurricane Katrina
  Cohen AN, Hyre A, Husserl F, Kutner N, Dreisbach A, Muntner P, JASN, 1/1/2007
• Cryptococcal Meningitis with Dermatological Manifestations in an HIV (-) Renal Transplant Patient
  Leder H A, Quintero C, Husserl, F, ACP, 1/1/2002
• Integration of Nephrology Clinic and Hemodialysis Personnel is a key Component to Creating an Effective Pre-End Stage Renal Disease Treatment Program
  French, MA, L Lindberg, JS, Filangeri J, James C, Slowik M, Tastet M, Sagastume R, Copley JB, National Kidney Foundation Professional Councils Conference, Toronto, Ontario, Canada, 1/12/2000
• The Impact of participation in a Healthy Start Clinic or ESRD/Hemodialysis (HD) initiation parameters
  Lindberg, JS, Copley JB, Elzein H, Husserl FE, Marquez AJ, 1/1/2000
• A 22 Month Follow-up Healthy Start Clinic Intervention in Pre-End Stage Renal Disease Patients
  Lindberg J, Filangeri J, James C, Jackson D, Tastet M. Szerlip M, Best J, Sadler R, Savoie J, Slowik M, Husserl FE, Copley JB, Clinical Nephrology Spring Meeting -NKF, 1/1/2000
• Relationships between agglomeration inhibition [tm] and urine parameters in calcium stone former
  Lindberg J, Roman W, Husserl F, Cole F, Kok D, Erwin D, ICN XVth International Congress of Nephrology, Buenos Aires, Argentina, 1/2/1999
• The Effect of Estrogen Replacement Therapy (ERT) on Agglomeration Inhibition In Postmenopausal Stone Formers (PSF)
  Romani W, Cole FE, Creighton A, Dey J, Kok DJ, Hamm L, Erwin D, James C, Thezan G, Husserl F, Copley J, Lindberg J, ASN, 1/1/1999
• An 18 Month Follow-up of Healthy Start Clinic (HSC) Intervention in Pre-ESRD Patients
  Lindberg J, Self I, Filangeri J, Becker A, Anderson S, Szerlip M, Best J, Sadler R, Savoie J, Slowik M, James C, Jackson D, Traina D, Husserl F, 1/1/1999
• Effect of Carnitine on Quality of Life in Chronic Hemodiaylysis Patients In and Out Patient Setting
  Rab ST, Lindberg J, Copley B, Figueroa J, Ross J, Marquez A, Husserl F, 1/1/1999
• Patient Perspective on Intervention with Healthy Start Clinic
  Best J, Lindberg J, Self I, Filangeri J, Becker A, Anderson S, Szerlip M, Sadler R, Savoie J, Slowik M, James C, Jackson D, Traina D, Husserl F, Eighth Annual Clinical Nephrology Meetings, 1/1/1999
• Clinical Trial of A New Graft Designed for Early and Chronic Vascular Access Compared with Conventional Access Grafts
  Lindberg J, Glickman M, Money S, Sternbergh W, Husserl F, JASN, 1/1/1998
• The Healthy Start Clinic: Tracking and Early Intervention in Pre-ESRD Patients
  Self I, Lindberg J, Slowik M, Filangeri J, Husserl F, Sadler R, Anderson S, Szerlip M, Best J, Becker A, NKF Spring Clinical Nephrology Meetings, 1/1/1998
• Agglomeration inhibition [tm] reflected stone activity during four years of potassium citrate therapy Kit-Cit-Rx) in calcium stone formers (CaSF)
  Lindberg J, Fuselier HA, Moore K, Husserl F, Cole FE, Whitehead D, Galliano D, Kok DJ, Erwin DT, American Society of Nephrology, San Antonio, TX, 1/2/1997
• Agglomeration Inhibition (tm) Reflects Stone Activity During 4 Years of Potassium Citrate Therapy in Calcium Stone Formers
  Lindberg J, Fuselier H, Moore K, Husserl F, et al, JASN, 1/1/1997
• Effects of Erythropoietin (EPO) on Prolactin Levels, Hypogonadism and Bone Density in Patients with Chronic Renal Failure
  Lindberg J, Smith S, Husserl FE, Ross J, Marquez-Julio A, Walker A, Naquin J, Burshell A, Copley J, NKF Spring Meetings, 1/1/1997
• Agglomeration Rate and Stone Formation
  Donaldson DS, Fuselier HA, Cole FE, Husserl FE, Kok DJ, Erwin DT, Lindberg JS, AUA, 1/1/1997
• Invitro Calcium Oxalate Monohydrate Agglomeration (TM) and Present Crystal Growth (% GI) Inhibited by Phosphocitrate (PC) Addition to Stone Formers in Urines
  Cole FE, Sallis JT, Lindberg J, Husserl F, Fuselier H, Kok DG, Erwin DT, 8th International Symposium on Ureterolithiasis, Dallas, TX, 1/1/1996
• Treatment of Calcium Oxalate Stone Formers with Potassium Citrate
  Lindberg J, Cole FE, Neusctzers S, Husserl F, Fuselier H, Kok D, Erwin DT, 8th International Symposium on Ureterolithiasis, Dallas, TX, 1/1/1996
• Urinary Inhibitors Before and During Potassium Citrate Therapy
  Erwin DT, Lindberg J, Husserl F, Fuselier H, Kok D, Cole FE, American Society of Nephrology, JASN, 1/1/1996
• A Profile of a Stone Forming Population from the Southern United States
  Erwin D, Kok D, Ward D, Neitzschman H, Fuselier H, Lindberg J, Husserl F, Cole F, Six European Symposium on Urolithiasis, Stockholm, Sweden, 1/8/1995
• Join now to see all

Lectures

• Evaluating Renal Function in the Primary Care Setting 
  New Orleans, LA - 1/1/2011
• Working with Non-adherent Patients: Challenges and Solutions 
  Lignano Sabbiadoro, Udine, Italy - 1/14/2008
• Ethical Dilemmas of Designing and Conducting Clinical Trials 
  Lignano Sabbiadoro, Udine, Italy - 1/14/2008
• Lazarus the Kidney Transplantee 
  1/1/2008
• Calciphylaxis Resolved after Treatment with Cinacalcet HCL for Secondary Hyperparathyroidism 
  1/1/2003
• Case Management for Early Intervention 
  Oklahoma City, OK - 1/9/2002
• Taller de Comunicacion 
  1/1/2002
• Care of the Renal Insufficient Patient 
  New Orleans, LA - 1/20/2001
• Comunicacion Paciente � Medico 
  Cali, Colombia - 1/15/2001
• Optimizacion del Manejo de un Paciente con Insuficiencia Renal Cronica 
  Cali, Colombia - 1/15/2001
• Hypertension Arterial 
  Ochsner-D�Antoni-La Ceiba, Honduras - 1/9/2001
• Manejo del Paciente Diabetico en Dialisis 
  Cartagena, Columbia - 1/1/2001
• Pre-Dialysis Education 
  1/1/2001
• Complications of Peritoneal Dialysis (Fundamentals of PD-Board Review) 
  1/1/2001
• Outpatient Iron Management 
  1/1/2001
• Nefropratia por Contraste 
  Cartagena, Columbia - 1/1/2001
• Cuando Iniciar Terapia de Remplazo Renal 
  Cartagena, Columbia - 1/1/2001
• Care and Management of Patients with CRF 
  Chabert Medical Center, Houma, LA - 1/1/2001
• Improving Patient Adherence 
  New Orleans, LA - 1/1/2000
• Changing for Good: A Framework for Improved Adherence in Dialysis 
  San Francisco, CA - 1/1/2000
• Behavioral Modification 
  Jackson, MS - 1/22/1999
• Dosis Adecuada de Dialisis Peritoneal. Ajuste de las Dosis en las Complicaciones de le Dialisis Peritoneal 
  Mexico City, Mexico - 1/13/1999
• Communication: A Prescription for Prevention 
  Boston, MA - 1/1/1999
• The Clinician as Agent of Change 
  1/1/1999
• Communication in Clinical Practice 
  1/1/1999
• Join now to see all